Natco Pharma eyes launch of 8-10 new drugs yearly in Indian market

Topics Natco Pharma | drugs

Natco Pharma aims to launch

around 10 new products every year in the Indian market, the city-based drug maker said on Thursday.

"Our strategy remains intact as we invest prudently in our research, manufacturing plants and enriching of skill sets. We are on track on our goal to launch 8-10 new products every year across our pharma business segments in India.

We also have some interesting filings and high-value launches in our international markets in the coming years," VC Nannapaneni, chairman of the company said in his speech at the Annual General Meeting.

During the year, Natco spent Rs 349 crore on capital expenditure, a majority of which was used to enhance capabilities of theirmanufacturing facilities.

A significant portion of thecapex was done at the company's facility in Visakhapatnam in Andhra Pradesh while the remaining part was primarily used in the formulation facilities across the country, he said.

With diversification and sustainability in mind, the company has invested in the Crop Health Sciences division targeting niche products.

A Greenfield project in Nellore district of Andhra Pradesh is close to completion and expected to be commissioned during FY 2020-21, he added.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel